MX2021014973A - Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. - Google Patents

Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.

Info

Publication number
MX2021014973A
MX2021014973A MX2021014973A MX2021014973A MX2021014973A MX 2021014973 A MX2021014973 A MX 2021014973A MX 2021014973 A MX2021014973 A MX 2021014973A MX 2021014973 A MX2021014973 A MX 2021014973A MX 2021014973 A MX2021014973 A MX 2021014973A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
high affinity
generation
affinity anti
Prior art date
Application number
MX2021014973A
Other languages
English (en)
Inventor
Robert Pejchal
Caitlin Stein
Julia Mccreary
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of MX2021014973A publication Critical patent/MX2021014973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos de unión a antígeno de estos con alta afinidad por CD3 y perfiles de capacidad de desarrollo convenientes, así como también métodos para su fabricación y uso.
MX2021014973A 2019-06-07 2020-06-08 Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. MX2021014973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858949P 2019-06-07 2019-06-07
PCT/US2020/036653 WO2020247929A1 (en) 2019-06-07 2020-06-08 High affinity anti-cd3 antibodies, and methods for their generation and use

Publications (1)

Publication Number Publication Date
MX2021014973A true MX2021014973A (es) 2022-04-18

Family

ID=73652645

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021014973A MX2021014973A (es) 2019-06-07 2020-06-08 Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.

Country Status (12)

Country Link
US (1) US20230002487A1 (es)
EP (1) EP3973000A4 (es)
JP (1) JP2022536247A (es)
KR (1) KR20220035369A (es)
CN (1) CN114174339A (es)
AU (1) AU2020288880A1 (es)
BR (1) BR112021020357A2 (es)
CA (1) CA3141909A1 (es)
IL (1) IL288607A (es)
MX (1) MX2021014973A (es)
SG (1) SG11202111329SA (es)
WO (1) WO2020247929A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002181A (es) * 2020-08-24 2023-03-02 Epimab Biotherapeutics Hk Ltd Anticuerpos anti-ror1 y proteinas de union biespecificas relacionadas.
WO2023178645A1 (zh) * 2022-03-25 2023-09-28 嘉和生物药业有限公司 靶向cd3的抗体及其应用
WO2024024882A1 (en) * 2022-07-28 2024-02-01 Chugai Seiyaku Kabushiki Kaisha Molecule specifically acting in a tissue where a cell death being observed
WO2024052831A1 (en) * 2022-09-09 2024-03-14 Janssen Biotech, Inc. Method of treating cancer with an anti tmeff2xcd3 bispecific antibody
WO2024086617A2 (en) * 2022-10-18 2024-04-25 Adimab, Llc Ph-dependent anti-cd3 antibodies and methods relating thereto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
RS58765B1 (sr) * 2011-05-21 2019-06-28 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
MX2016007958A (es) * 2013-12-17 2016-08-03 Genentech Inc Anticuerpos anti-cd3 y metodos de uso.
EP4276116A3 (en) * 2015-04-17 2024-01-17 Amgen Research (Munich) GmbH Bispecific antibody constructs for cdh3 and cd3
MX2018000347A (es) * 2015-07-15 2018-03-14 Genmab As Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
WO2018043311A1 (ja) * 2016-08-31 2018-03-08 オンコセラピー・サイエンス株式会社 Ｍｅｌｋに対するモノクローナル抗体およびその使用
BR112019012901A2 (pt) * 2016-12-22 2020-01-07 Daiichi Sankyo Company, Limited Anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo e uma molécula que se ligue ao cd3 humano e ao cd3 de macaco cinomolgo, composição farmacêutica, e, molécula
CN106831996B (zh) * 2017-03-31 2020-05-19 北京智仁美博生物科技有限公司 具有cd3e和/或her2靶向功能的双特异性抗体及其用途
SG10201912494TA (en) * 2017-05-08 2020-02-27 Adimab Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
EP3668898B1 (en) * 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
AU2018336519A1 (en) * 2017-09-21 2020-03-05 WuXi Biologics Ireland Limited Novel anti-CD3epsilon antibodies

Also Published As

Publication number Publication date
WO2020247929A8 (en) 2021-07-22
BR112021020357A2 (pt) 2021-12-14
AU2020288880A1 (en) 2021-11-11
IL288607A (en) 2022-02-01
US20230002487A1 (en) 2023-01-05
JP2022536247A (ja) 2022-08-15
KR20220035369A (ko) 2022-03-22
SG11202111329SA (en) 2021-12-30
EP3973000A1 (en) 2022-03-30
CN114174339A (zh) 2022-03-11
CA3141909A1 (en) 2020-12-10
WO2020247929A1 (en) 2020-12-10
EP3973000A4 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
MX2021014973A (es) Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso.
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
PH12020551948A1 (en) Monospecific and multispecific anti-tmeff2 antibodies and their uses
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
EP4414034A3 (en) Antibodies specific for cd3 and uses thereof
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
EP3980465A4 (en) MODIFIED PH-DEPENDENT ANTI-CD3 ANTIBODIES, AND METHODS OF GENERATION AND USE THEREOF
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2021008621A (es) Anticuerpos de inmunoglobulina a y metodos de produccion y uso.
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
MX2021015301A (es) Métodos de cultivo celular y composiciones para la producción de anticuerpos.
MX2022000379A (es) Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas.
ZA202305072B (en) Cd1a antibodies and uses thereof
EP4061840A4 (en) ANTI-ALPHA-SYNUCLEIN MONOCLONAL ANTIBODIES, AND CORRESPONDING METHODS OF USE
EA202091053A1 (ru) Модифицированные c- и ch1-домены
MX2024002962A (es) Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo.